Dr. Reddy’s Laboratories is in the spotlight today as the European Commission (EC) has granted marketing authorization for its biosimilar AVT03, a denosumab-based treatment that rivals Prolia and Xgeva. This is a major win for Dr. Reddy’s as the approval covers all EU member states plus Iceland, Liechtenstein, and Norway. AVT03 is being developed in partnership with Alvotech, where Dr. Reddy’s handles registration and commercialization. Once fully launched, Dr. Reddy’s will market the drug under the names Acvybra (60 mg syringe) and Xbonzy (70 mg vial). Investors responded positively — Dr. Reddy’s shares jumped around 1.5% on the news. This approval strengthens the company’s biosimilar portfolio and its presence in the European biologics market. The strategic move could also enhance patient access to Dpboss more affordable bone-strengthening treatments across Europe.